Search Results

WP1130 10mg 10mg  | Purity Not Available

Adooq Bioscience

WP1130 (Degrasyn) is a novel selective small molecular deubiquitinase inhibitor and a Bcr/Abl destruction pathway activator that specifically and rapidly down-regulates both wild-type and mutant Bcr/Abl protein without affecting bcr/abl gene expression in chronic myelogenous leukemia (CML) cells.

More Information Supplier Page

VX-809 50mg 50mg  | Purity Not Available

Adooq Bioscience

VX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).

More Information Supplier Page

VX-809 5mg 5mg  | Purity Not Available

Adooq Bioscience

VX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).

More Information Supplier Page

WYE-354 25mg 25mg  | Purity Not Available

Adooq Bioscience

WYE-354 is a potent cell-permeable inhibitor of mTOR (IC50 = 4.3 nM) which blocks signaling through both mTOR complex 1 (mTORC1) and mTORC2. It is a much weaker inhibitor of PI3K ?? (IC50 = 1026 nM) and other kinases.

More Information Supplier Page

WYE-354 5mg 5mg  | Purity Not Available

Adooq Bioscience

WYE-354 is a potent cell-permeable inhibitor of mTOR (IC50 = 4.3 nM) which blocks signaling through both mTOR complex 1 (mTORC1) and mTORC2. It is a much weaker inhibitor of PI3K ?? (IC50 = 1026 nM) and other kinases.

More Information Supplier Page

WZ4002 10mM * 1mL in DMSO 10mM * 1mL in DMSO  | Purity Not Available

Adooq Bioscience

WZ4002 is EGFR inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) which is detected in 50% of clinically resistant patients to gefitinib or erlotinib.

More Information Supplier Page

WZ4002 100mg 100mg  | Purity Not Available

Adooq Bioscience

WZ4002 is EGFR inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) which is detected in 50% of clinically resistant patients to gefitinib or erlotinib.

More Information Supplier Page

WZ4002 10mg 10mg  | Purity Not Available

Adooq Bioscience

WZ4002 is EGFR inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) which is detected in 50% of clinically resistant patients to gefitinib or erlotinib.

More Information Supplier Page

WZ3146 50mg 50mg  | Purity Not Available

Adooq Bioscience

WZ3146 is an inhibitor of EGFR receptor kinase mutants carrying a mutation in an active site gatekeeper residue (T790M) and is much less potent against wild-type EGFR kinase.

More Information Supplier Page

WZ3146 5mg 5mg  | Purity Not Available

Adooq Bioscience

WZ3146 is an inhibitor of EGFR receptor kinase mutants carrying a mutation in an active site gatekeeper residue (T790M) and is much less potent against wild-type EGFR kinase.

More Information Supplier Page